Chiome Bioscience Inc.
Tokyo Stock ExchangeTotal Valuation
Chiome Bioscience Inc. carries a market capitalization of 5.74B, placing it among publicly traded companies globally. Its enterprise value stands at 6.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.74B |
| Enterprise Value | 6.79B |
Share Statistics
Chiome Bioscience Inc. currently has 56.38M shares outstanding.
| Shares Outstanding | 56.38M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 12.95, and the price-to-book ratio stands at -34.18.
| PE Ratio | N/A |
| PS Ratio | 12.95 |
| PB Ratio | -34.18 |
| P/TBV Ratio | 7.10 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 11.56 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 2,771.32 |
Financial Position
Chiome Bioscience Inc. maintains a current ratio of 3.29, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.29, indicating elevated leverage, while an interest coverage ratio of -461.72 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.29 |
| Quick Ratio | 2.55 |
| Debt / Equity | 27.29 |
| Debt / EBITDA | -0.26 |
| Interest Coverage | -461.72 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -69.09 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.68 |
Taxes
| Income Tax | 4.42M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Chiome Bioscience Inc.'s stock has declined approximately -44.75524% over the past 52 weeks. The 50-day moving average sits at 82.88, while the 200-day moving average is 107.70.
| Beta (5Y) | N/A |
| 52-Week Price Change | -44.75524% |
| 50-Day Moving Average | 82.88 |
| 200-Day Moving Average | 107.70 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Chiome Bioscience Inc. generated 587.30M in revenue and converted that into -1.12B in net income, yielding earnings per share of -20.63. EBITDA reached -1.13B, while operating income came in at -1.13B.
| Revenue | 587.30M |
| Gross Profit | 324.68M |
| Operating Income | -1.13B |
| Pretax Income | -1.12B |
| Net Income | -1.12B |
| EBITDA | -1.13B |
| EBIT | -1.13B |
| Earnings Per Share (EPS) | -20.63 |
Balance Sheet
Chiome Bioscience Inc. holds 1.10B in cash and equivalents against 292.10M in total debt, resulting in a net debt position of -811.56M. Total book value stands at -222.46M, with working capital of 989.40M providing operational flexibility.
| Cash & Cash Equivalents | 1.10B |
| Total Debt | 292.10M |
| Net Debt | -811.56M |
| Equity (Book Value) | -222.46M |
| Book Value Per Share | -4.10 |
| Working Capital | 989.40M |
Margins
Chiome Bioscience Inc. operates with a gross margin of 55.28, reflecting its pricing power and cost economics. The operating margin of -191.90 and net profit margin of -190.76 provide insight into operational efficiency.
| Gross Margin | 55.28 |
| Operating Margin | -191.90 |
| Pretax Margin | -190.00 |
| Profit Margin | -190.76 |
| EBITDA Margin | -191.90 |
Stock Splits
Chiome Bioscience Inc.'s most recent stock split took place on March 27, 2014 with a 1:2 split ratio.
| Last Split Date | 3/27/2014 |
| Split Ratio | 1:2 |
Scores
Chiome Bioscience Inc. posts an Altman Z-Score of 7.61, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.61 |